Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498400 | 0.86 | EPHX1 (0.43) | ALDH1A1MAPTEPHX1 | |
| Bromide SCHEMBL6500845 | 0.85 | EPHX1 (0.43) | ALDH1A1MAPTEPHX1 | |
| Bromide SCHEMBL6426590 | 0.85 | EPHX1 (0.43) | ALDH1A1MAPTEPHX1 | |
| SCHEMBL6427826 | 0.81 | KMT2A (0.45) | ALDH1A1MAPT | |
| SCHEMBL6427832 | 0.81 | ALDH1A1 (0.33) | MAN1B1ALDH1A1MAPTTDP1 | |
| Bromide SCHEMBL6508115 | 0.80 | GLA (0.36) | MAN1B1ALDH1A1MAPT | |
| SCHEMBL6428894 | 0.77 | P2RX7 (0.37) | GBA1ALDH1A1 | |
| SCHEMBL6426173 | 0.75 | EPHX1 (0.40) | GBA1ALDH1A1EPHX1 | |
| SCHEMBL1605496 | 0.74 | EPHX2 (0.37) | GBA1ALDH1A1MAPTEPHX1TDP1 | |
| SCHEMBL6389539 | 0.74 | DAPK3 (0.40) | ROCK1ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | GBA1 920/4885GRIN2B 1742/4885MAN1B1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.